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ABSTRACT 
 Aim: Elaeocarpus ganitrus (Family: Elaeocarpaceae), has shown beneficial role in the 
treatment of depression, convulsions and asthma. This study was undertaken to evaluate the 
antiparkinson effect of E.ganitrus. Materials and methods: Swiss albino mice of either sex 
were divided into 06 groups (n =12). 1st group mice were given 0.5% carboxy methyl 
cellulose (orally), 2nd group were administered MPTP (2 doses, each dose 20 mg/kg at 2 hr. 
interval, i.p.). Whereas 3rd, 4th and 5th groups - were administered with E. ganitrus (100, 
200, and 400 mg/kg/day, orally), respectively, along with MPTP. Group 6- received 
Levodopa (30mg/kg, i.p,) along with MPTP. To evaluate anti-Parkinson effect, hanging wire 
test, tardive dyskinesia test and elevated plus maze test were performed on the1st day and on 
8th day. One way ANOVA followed by post-hoc Tukey test, with p<0.05 was considered 
statistical significant. Results: E.ganitrus (200 and 400 mg/kg, p.o.) was found to increase 
the hanging time significantly (p <0.001) in hanging wire test and significantly decreased (p 
<0.001) the Vacuous Chewing Movements (VCMs) in tardive dyskinesia test as compared to 
MPTP group. E.ganitrus (200 and 400 mg/kg, p.o.) was found to significantly increase (p 
<0.001) the no. of entries and time spent in open arm and significantly decreased the no. of 
entries and time spent in closed arm (p <0.001) compared to MPTP treated group. 
Conclusion: The results of the present study conclusively showed that E.ganitrus has 
beneficial effect in MPTP induced experimental model of Parkinson’s disease. 
Introduction 
Plants remain as important  source of medicine over the years 
to treat many diseases [1]. Decoctions prepared from fruits of 
Elaeocarpus ganitrus (E.ganitrus) have showed better results 
in the treatment of epilepsy, asthma, liver disorder, dropsy and 
hypertension [2, 3]. In addition to these benefits, E. ganitrus 
has found to exhibit many pharmacological activities that 
include analgesic [4], smooth muscle relaxant effects [5]. 
Parkinson’s disease is a chronic progressive 
neurodegenerative disorder resulting from idiopathic 
degeneration of dopaminergic cells in the substantia nigra pars 
compacta [6].While the causative factors for the degeneration 
of dopaminergic cells in the substantia nigra pars compacta is 
still not well established, oxidative stress might play an 
important role [7]. 
Levodopa remains the most efficacious drug in 
pharmacotherapy of Parkinson’s disease. However, long-term 
use of levodopa causes disabling motor complications like 
dyskinesia’s and on-off phenomenon. Because of the concern 
over the side effects of allopathic medicines, the use of natural 
products which may serve as better alternative to existing 
treatment needs to be explored. Thus, strategies employing 
antioxidant activity with lesser side effects from natural 
          CODEN (USA): IJPB07                                                                     ISSN: 2320-9267   
                                                                    
Indian Journal of Pharmaceutical and Biological Research (IJPBR) 
Journal homepage: www.ijpbr.in 
Bagewadi HG et al. / Indian J. Pharm. Biol. Res., 2015; 3(2):1-6 
 
Original Research Article 2 
 
sources can be a good approach in improving the treatment of 
Parkinson’s disease. 
Chronic treatment with neuroleptics leads to the development 
of abnormal oral movements in rodents known as vacuous 
chewing movements (VCMs). Vacuous chewing movements 
in rats are widely accepted as an animal model of tardive 
dyskinesia[8]. The hang test mainly evaluates the 
neuromuscular strength, coordination and is sensitive to a loss 
of dopamine[9]. Anxiety symptoms are very common in PD 
patients and some author’s state that anxiety in PD can be 
manifested even before the emergence of the first motor 
symptoms[10,11]. 
Previous studies undertaken by us shows that E. ganitrus[12] 
possess antioxidative properties and showed beneficial effect 
in rotarod test and catalepsy bar tests which are behavioral 
models of parkinson disease. The present study was 
undertaken in order to further strengthen the evidence of 
protective role of E. ganitrus in 1-methyl-4-phenyl-1, 2, 3, 6-
tetrahydropyridine (MPTP) induced Parkinsonism using 
different behavioral assessment parameters like-hanging wire 
test, tardive dyskinesia test, elevated plus maze tests. Previous 
study done by us showed the antiparkinsonian effect of 
E.ganitrus in haloperidol induced parkinsonian model in these 
behavioral tests. The different doses of ethanolic extract of 
E.ganitrus were chosen from other previous studies 
conducted by Kakalij RM et al [13]. 
Materials and methods 
Swiss albino mice of either sex weighing between 25 and 30 
g, were obtained from the central animal house of University 
College of Medical Sciences and GuruTeg Bahadur Hospital. 
The mice were housed in cages and kept under controlled 
environmental condition (temperature 22±2 °C, humidity 
50–55 %, natural light/day cycle). Care of animals was given 
according to the CPCSEA guidelines. Permission was taken 
from the Institutional Animal Ethics Committee to carry out 
the study (Approval No. IAEC/2011/49 dated 10 March 
2011).  
Plant extract and Chemicals: E.ganitrus extract was 
obtained from M/s Tapovan ayurved sadan, New Delhi. As 
per the literature provided by the manufacturer, initially the 
dried fruits of E.ganitrus Roxb were taken and crushed into a 
fine powder. 200 gms of the drug was soaked in 90% ethanol 
for 48 hrs. Percolation was carried out by Soxhlet apparatus 
through suction method. Filtration was performed repeatedly 
with the help of whatman filter paper No-4 and filtrate was 
air dried sufficiently. Then the dried extracts were stored at 
4oC until its further usage. The yield of the drug was found 
to be 05.72% (w/w in terms of dried starting material). To 
carry out our study, the E.ganitrus powder was dissolved in 
0.5% Carboxy methyl cellulose (CMC) to prepare 
suspensions of different doses of 100, 200 and 400 mg/kg. 
MPTP and Levodopa was obtained from Sigma Chemical 
Co. USA.  
Experimental Design 
Swiss albino mice (6 weeks old) of either sex weighing 
between 25 and 30 gms, were used for the study. The mice 
were divided into 06 groups (n =12).Group I- was 
administered 0.5% carboxy methyl cellulose (orally ×1 
weeks). Group II- received MPTP (2 doses, each dose 20 
mg/kg at 2 hr. interval, i.p. daily x 1 week). Groups III, IV, 
and V- were treated with E.ganitrus (100, 200, and 400 
mg/kg/day, orally), respectively for 1 week along with 
MPTP. Group VI- received Levodopa (30mg/kg, i.p, once 
per day x 1 week) along with MPTP. The E.ganitrus (100 
mg/kg, 200mg/kg, 400 mg/kg, orally) and Levodopa (30 
mg/kg, i.p.) were given 30 minutes prior to injections of first 
dose of MPTP for 7 days of experimental period. The 
behavioral parameters were assessed on 1st day and on 8th day.  
Assessment of behavioral tests 
1. Hang test: Neuromuscular strength was determined in the 
grid hang test. Mice were lifted by their tail and slowly 
placed on a horizontal grid and supported until they 
grabbed the gird with both their fore and hind paws. The 
grid was then inverted so that the mice were allowed to 
hang upside down. The grid was mounted 20 cm above a 
hard surface, to discourage falling but not leading to 
injury in case of animal fall. The apparatus was equipped 
with a 3-inch wall to prevent animals from transversing to 
the upper side of the grid. Animals were required to stay 
on the grid for 30 seconds. The animals were tested in the 
grid hang test for 30 sec and 10 chances were given with 
1min interval and maximum hanging time was 
recorded[14]. 
2. Tardive dyskinesia test: Tardive Dyskinesia is referred 
to as Vacuous Chewing Movements (VCMs) in rodents. 
On the test day mice were placed individually in a small 
(30× 20× 30 cm) Plexiglas cage for the assessment of oral 
dyskinesia. Animals were allowed 10 min to get used to 
the observation cage before behavioral assessments. In the 
present study vacuous chewing movements are referred to 
as single mouth openings in the vertical plane not directed 
toward physical material. If tongue protrusion and 
vacuous chewing movements occurred during a period of 
grooming, they were not taken into account. Mirrors were 
placed under the floor and behind the back wall of the 
cage to permit observation of oral dyskinesia when the 
animal was faced away from the observer. The behavioral 
parameters of oral dyskinesia were measured 
continuously for a period of 5 min[15]. 
3. Hole board test: Head dipping is an exploratory behavior 
of the animals in the Hole Board test which is considered 
to be an indicator of anxiety. Mice were placed in a black 
Perspex box (50 x 50 cm, walls 30 cm high) with 16 
equally spaced holes (2.5 cm diameter, 10 cm apart from 
each other) in the floor and the box was raised to a height 
of 25cms from the ground. An animal was placed in the 
center of the hole-board and allowed to freely explore the 
apparatus for 5 min. The total no. of lines crossed and the 
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number of head dippings were recorded. A head dip was 
scored if both eyes disappeared into the hole[16]. 
Statistical Analysis 
Results of the above experiments were expressed as Mean ± 
SEM, and the difference between means was analyzed by 
analysis of variance (ANOVA) using graph pad prism 
followed by pos t -hoc Tukey tes t ,  wi th P < 0.05  
being considered as  st at i s t ical  s igni f i cant .   
 
Results 
Table1: Effect of E.ganitrus on hanging wire test in MPTP treated mice 
 
Groups, (Dose) Hanging time in (Sec) -1st day Hanging time in (Sec) -8th day 
1. CMC (1ml/kg, p.o) 37.8 ±1.52 39.16± 1.37 
2. MPTP (20 mg/kg, i.p.) 15.8±1.75* 14.7±2.44* 
3. E.ganitrus (100mg/kg, i.p.) +MPTP 16.7±1.64*, ‡ 18.5±2.76*, ‡ 
4. E.ganitrus (200mg/kg, i.p.) +MPTP 20.1±2.07*, ‡ 25.8±3.17*, † 
5.E.ganitrus (400mg/kg, i.p.) +MPTP 21.5±3.15*, ‡ 29.2±3.26*, †, ‡ 
6.Levodopa (30 mg/kg, i.p.) +MPTP 31.5±4.69*, † 34.5±3.74*, † 
The results are expressed as mean ± SD for 12 animals in each group. 
*p < 0.001 vs. Carboxy methyl cellulose (CMC) - control, †p < 0.001 
vs.MPTP, ‡p < 0.001 vs. (Levodopa + MPTP) 
It was observed that MPTP alone treated group, significantly 
decreased the hanging time (p<0.001) on 1st day and 8th day 
as compared to control group. In Levodopa treated group, 
significant increase in hanging time (p<0.001) was seen on 
both 1st day and 8th day, as compared to MPTPtreated group. 
E.ganitrus100mg/kg, 200mg/kg and 400mg/kg pretreated 
groups did not cause any significant change in hanging time 
on 1st day. But on 8th day, E.ganitrus200 mg/kg and 
400mg/kg pretreated groups showed significant increase in 
hanging time (p<0.001) when compared to MPTP (as shown 
in table 1).Whereas no significant difference in hanging time 
was seen when E.ganitrus400 mg/kg treated group compared 
to levodopa treated group. 
Table2:Effect of E.ganitrus on tardive dyskinesia in MPTP treated mice 
Groups, (Dose) VCMs/5 min -1st day VCMs/5min -8th day 
1. CMC (1ml/kg, p.o) 12.5±1.36 13.3±1.61 
2. MPTP (20 mg/kg, i.p.) 54.3+3.27* 59.6+3.75* 
3. E.ganitrus (100mg/kg,i.p.) +MPTP 50.1+1.48*, ‡ 44.3+2.32*, ‡ 
4. E.ganitrus (200mg/kg,i.p.) +MPTP 51.3±3.68*, ‡ 24.7±4.36*, †, ‡ 
5. E.ganitrus (400mg/kg,i.p.) +MPTP 49.5±3.21*, ‡ 21.3±2.31*, † 
6. Levodopa (30mg/kg,i.p.) +MPTP 18.7±4.38*, † 16.8±4.27*, † 
The results are expressed as mean ± SD for 12 animals in each group. *p < 
0.001 vs. Carboxy methyl cellulose (CMC) - control, †p < 0.001 vs. MPTP, 
‡p < 0.001 vs. (Levodopa + MPTP). 
It was observed that among MPTP alone treated group, 
significant increase p<0.001 in vacuous chewing movements 
(VCMs) was seen on 1st day and on 8th day when compared to 
control group. In Levodopa treated group, significant decrease 
in (VCMs)   p<0.001 was seen on 1st day and 8th daywhen 
compared to MPTP treated group. E.ganitrus100mg/kg, 
200mg/kg and 400mg/kg pretreated groups did not cause any 
significant change in (VCMs) on the 1st day. But on 8th day, 
E.ganitrus200mg/kg and 400mg/kg pretreated groups 
showed significant decrease in (VCMs) p<0.001 when 
compared to MPTP treated group (as shown in table 2), 
whereas no significant difference in (VCMs) was seen when 
E.ganitrus 400 mg/kg treated group compared to levodopa 
treated group. 
Table 3:Effect of E.ganitrus in tail suspension test on 1st day and 8th day 
Groups, (Dose) Duration of Immobility (sec) -1st day Duration of  Immobility (sec) -8th day 
1. CMC (1ml/kg, p.o) 179.5± 2.91        183.5±2.73        
2. MPTP(20 mg/kg, i.p.) 254.7±2.84*  262.7± 2.52* 
3. E.ganitrus(100mg/kg,i.p.) + MPTP 246.3±2.61*, ‡ 241.3±2.19*,†, ‡ 
3. E.ganitrus(200mg/kg,i.p.) + MPTP 171.2±3.95*, ‡ 97.4±1.37*,†, ‡ 
4. E.ganitrus(400mg/kg,i.p.) + MPTP 111.6±2.35*, ‡ 88.2±1.54*, † 
5.Levodopa (30mg/kg,i.p.) +MPTP      90.4±1.21*, † 82.3±3.02*, † 
(n=12), values expressed as mean±SEM. (*p< 0.001 vs. normal saline-control), (†p< 0.01 vs. MPTP), (‡p< 0.01,vs. Levodopa+MPTP) 
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In group treated with MPTP, animals showed significant 
increase (p<0.01) in immobility period in tail suspension 
test, on 1st day and 8th day when compared to control group 
(as shown in table 3). The group treated with Levodopa as a 
standard, animals showed significant decrease (p<0.001) in 
immobility period on 1st day and 8th day as compared to 
control group (as shown in table 3).When E.ganitrus 
200mg/kg and 400mg/kg pretreated groups when compared 
to control group, animals showed slight decrease in the 
period of immobility on 1stday which was not statistically 
significant. Whereas, on 8thday, a significant decrease 
(p<0.001) in immobility period was noticed (as shown in 
table 3).But on 8th day there was no statistically significant 
difference in the immobility period when E.ganitrus 
400mg/kg pretreated groups compared to Levodopa treated 
group (as shown in table 3).  
Discussion 
Parkinson’s disease is a progressive neurodegenerative 
disorder, characterized by resting tremor, bradykinesia, 
flexed posture, shuffling gait and rigidity. The cause for 
dopaminergic neuronal degeneration is still not well 
established, but oxidative stress might play significant role 
[7].Oxidative stress may result from generation of free radical 
reactive species during the metabolism of dopamine [17]. The 
substantia nigra pars compacta is relatively more succumbed 
to generation of free radical reactive oxygen species 
amounting to more oxidative stress. 
This excess generation of free radical reactive oxygen species 
might be directly correlated to the high energy metabolism or 
to more content of dopamine in these cells [18]. Several 
studies have established the finding that oxidative stress 
changes are demonstrable in the brain of Parkinson’s disease 
patients [19]. 
(MPTP), 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine is a 
potent neurotoxin used to create an experimental model of 
Parkinson’s disease in animals. Certain aspects of the 
Parkinson’s disease such as catalepsy, motor incoordination 
and bradykinesia can be easily studied in this model. As 
MPTP is highly lipophilic, makes it enable to cross the blood 
brain barrier immediately after its systemic absorption. Once 
MPTP reaches the brain tissue, it is converted to the 
hydrophilic metabolite 1-methyl-4 phenylpyridinium ion 
(MPP+), the free radical reactive specie in the causation of 
dopaminergic neuronal loss. It is established that these free 
radical reactive species play a vital role in the pathogenesis 
of dopaminergic neuronal loss in Parkinson’s disease [20]. 
E.ganitrus is an important medicinal plant which has proved 
its benefits in various neurological diseases caused by 
oxidative stress. It is convincingly explained that antioxidants 
might be effective in PD by preventing neuronal death which 
is caused by intracellular free radicals[7]. 
The mice when pretreated with E.ganitrus (200, 400 mg/kg, 
p.o.) for 8 days, significantly increased the hanging time in 
hanging wire test, decreased the vacuous chewing movements 
(VCMs) in tardive dyskinesia test and this effect is 
comparable to that of levodopa group. The above findings of 
behavioral tests are similar with other previous 
studies[21,22].The mice when pretreated with E.ganitrus 
(200, 400 mg/kg, p.o.) for 8 days, significantly increased the 
duration of immobility in tail suspension test this effect is 
comparable to that of levodopa group. The above findings of 
behavioral tests are similar with other previous studies done 
on different parkinsonian animal models induced by MPTP 
and haloperidol [23-25]. 
The role of neuroinflammation and usage of anti-
inflammatory medication in the prevention of Parkinson’s 
disease still needs to be well established. However, some 
animal experimental studies have showed preventative role 
of nonsteroidal anti-inflammatory drugs (NSAID’s) in 
Parkinson’s disease. Recently, it became evident that 
inflammatory process contributes significantly to the 
pathogenesis of Parkinson’s disease [18, 26]. Previous 
studies have established the finding that anti-inflammatory 
drugs such as acetylsalicylic acid can prevent MPTP induced 
Parkinson’s disease in mice [27]. It is widely accepted that 
inflammation and oxidative stress both are interrelated. It is 
interesting to know that oxidative stress can potentiate 
inflammatory process and inflammation is found to generate 
oxidative stress [27]. Anti-inflammatory activity was 
demonstrated by the several fruit extracts of E.sphaericus like 
petroleum ether, benzene, chloroform, acetone and ethanol 
extracts in rats [28]. The key ingredients identified after 
phytochemical screening of ethanolic extract of fruits were 
alkaloids, flavonoids, carbohydrates, proteins and tannins[29]. 
The ethanolic extract of leaves of E.ganitrus isalso known to 
contain quercetin, gallic and ellagic acids (elaeocarpine, 
isoelaeocarpine)[30]. The major phytoconstituents of 
E.sphaericus are mainly alkaloids like- elaeocarpidine, 
elaeocarpine[31], and rudrakine[32]. Flavonoids like 
quercetin[33], phenolics are also important phytoconstituents 
of E.sphaericus. Increased antioxidants activities and 
decreased levels of lipid peroxides were seen in the brains of 
mice pretreated with E.ganitrus convincingly demonstrated 
that the extract significantly reduces oxidative stress. Our 
study findings are in accordance with previous studies done by 
Reddy VVM et al [34] and Bagewadi HG et al [35]. It is also 
established that Flavonoids content in E.ganitrus leaves has 
marked antioxidant activity[36]. 
The anti-Parkinsonian effect of E.ganitrus may be attributed to 
the presence of alkaloids and flavonoids having marked 
antioxidant and anti-inflammatory properties. However, 
further studies should be undertaken to identify and 
investigate the mechanism of action of active antiparkinsonian 
compounds in E.ganitrus. The behavioral assessment of motor 
imbalance, tardive dyskinesia and antiparkinsonian activity of 
E.ganitrus has to be further explored in other experimentally 
induced Parkinsonism models like Reserpine, 6-OHDA (6-
Hydroxy dopamine). 
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Conclusion 
Parkinson’s disease is a progressive neurodegenerative 
disease accompanied by preferential loss of dopaminergic 
neurons of the substantia nigra pars compacta. MPTP is a 
potent neurotoxin, commonly used to create experimental 
model of Parkinson’s disease. The results of the present study 
conclusively showed that E.ganitrus has beneficial effects in 
hang wire test, tardive dyskinesia test and elevated plus maze 
test. In this regard, future studies on this topic may provide an 
elaborate view to use E. ganitrus in clinical medicine for 
treatment of Parkinson’s disease and its neurological sequel. 
Conflict of interest: We declare that we have no conflict of 
interest. 
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